Orchid BioSciences and Thermo Electron to Develop Genotyping Products
PRINCETON, N.J., and WALTHAM, Mass., March 6 -- Orchid BioSciences Inc. and Thermo Electron Corp. announced they have signed technology agreements to develop and market next-generation genotyping products for research and pioneering SNP-based point-of-care diagnostic tests. SNPs(single-nucleotide polymorphisms) are single base-pair sequence variations in DNA that can affect medically important factors such as antibiotic resistance, response to therapy, disease susceptibility and genetic disorders.
The agreements, between Orchid and Thermo Electron’s Thermo BioStar business, allow Orchid nonexclusive rights from Thermo BioStar to develop, supply and sell genotyping products for the research market, combining Orchid’s proprietary SNP-IT genotyping and Thermo BioStar’s OIA and thin-film biosensor technologies. Orchid and Thermo BioStar have also agreed to jointly develop and market SNP-based diagnostic products for the point-of-care marketplace.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024